Emerging and Mid-Sized Biopharma

Technology and expertise
to fit your needs

Emerging and Mid-Sized Biopharma companies rely on Medidata to gain speed, scale as complexity increases, mitigate risks, and improve trial outcomes.

Medicenna: Solving the Impossible in Glioblastoma with Medidata Acorn AI Synthetic Control Arm® (SCA®)

Hear how Medicenna Therapeutics, Inc worked with the Acorn AI team to become the first to get an FDA agreement to design a phase 3 registrational trial using an external control arm.

One technology platform to power people, processes, and progress.

Medidata helps Emerging and Mid-Sized Biopharma companies adapt, simplify, scale, and accelerate their clinical trials, from protocol design to study startup, conduct, close-out, and commercialization. Our platform is built to enable you with cloud-based, modular, integrable, easily configurable capabilities, all powered by the latest patient, clinical and operational data, and AI solutions.

The industry’s only complete decentralized clinical trial solution

There’s no doubt about it. The decentralized trial is here to stay. That leaves leaders of emerging and mid-sized biopharma with one question: Who can help you start running easy-to-implement and cost-effective virtual, hybrid, and decentralized trials right now?

Truth in data:

  • 800+ studies
  • 600K+ patients
  • 44K+ sites using a Medidata DCT solution

Read more about our end-to-end decentralized clinical trial solutions for emerging and mid-sized biopharma.

The industry’s only platform to leverage cross-industry clinical trial data

You need faster insights for faster action. Not disparate data from disparate sources. Elevate your organization and future-proof your trials with connected, standardized data – for clearer visibility across trials and more actionable insights.

Truth in data:

  • Clinical trial data from 7 million patients and 25,000+ trials
  • 45B+ data points
  • 63% growth in data volume in 4 years

Learn more about our data and analytics solutions for emerging and mid-sized biopharma.

The results-driven approach to unifying teams, data, and processes

Do more with less by unifying your teams, data, applications, and processes in one easily accessible place. With a seamless and intuitive cloud-based platform, you can enhance visibility across trials, increase operational efficiencies, and decrease trial timelines.

Truth in data:

  • 5 days to reach database lock
  • 80% reduction in data correction rates
  • 40% reduction in edit checks

Learn more about our unified technology platform for emerging and mid-sized biopharma.

The industry’s most comprehensive patient-centric solutions

Regardless of the size of your organization, patients are at the heart of everything you do. From patient enrollment to retention, we help emerging and mid-sized biopharma engage more patients -more effectively- with trial decentralization and patient-first tech at every step.

Truth in data:

  • Cross-industry clinical trial data from over 25,000 trials and over 7 million patients
  • Datasets pre-integrated with real world data

Learn more about our patient-centric clinical trial solutions for emerging and mid-sized biopharma.

Resources for Mid-Sized Biopharma

GUIDE
Decentralized Clinical Trial Technology

Decentralized Clinical Trial Technology

Disruptions preventing or limiting site access to patients, monitors, and CRAs are propelling long-lasting changes.

Are you set to adopt a decentralized clinical trial strategy?

VIDEOS
Pivot Faster

Pivot Faster

Hear how executives at TissueTech, Rezolute, and UroGen Pharma have achieved greater pace and performance results.

 

eBOOK
The Data to Increase Success

The Data to Increase Success

Data is at the core of study success.

Optimize trial design, accelerate patient enrollment, improve operations, and proactively improve data quality.